Corpus Intelligence IC Memo — UNIVERSITY OF KANSAS HOSPITAL 2026-04-26 04:03 UTC
IC Memo — UNIVERSITY OF KANSAS HOSPITAL
Investment Committee Memorandum | KS | 955 beds | Grade B | EBITDA uplift $190.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF KANSAS HOSPITAL

CCN 170040 | WYANDOTTE, KS | 955 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF KANSAS HOSPITAL is a 955-bed large academic medical center in WYANDOTTE, KS with $2.58B in net patient revenue and a -38.4% operating margin. The hospital serves a payer mix of 24.6% Medicare, 4.3% Medicaid, and 71.1% commercial.

Thesis: Undervalued. Our ML models identify $190.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -38.4% to -31.1% (+736bps).

Net Revenue HCRIS$2.58B
Current EBITDA COMPUTED$-993.3M
Operating Margin COMPUTED-38.4%
Occupancy HCRIS77.0%
Revenue / Bed COMPUTED$2.7M
Net-to-Gross HCRIS20.0%
Distress Probability ML41.4%

2. Market Context & Competitive Position

152
KS Hospitals
-17.7%
State Median Margin
292
Comparable Hospitals

KS has 152 Medicare-certified hospitals with a median operating margin of -17.7%. The target's margin of -38.4% places it below the state median. Among 292 size-comparable peers (478-1910 beds), the median margin is -4.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (478-1910), prioritizing same-state peers. 292 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF KANSAS HOSPITAL (Target)KS955$2.58B-38.4%
ST. LUKES HOSPITALPA633$8.94B87.9%
NYU LANGONE HOSPITALSNY1618$7.24B-7.8%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $190.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$54.3M+210bp18mo
Cost to Collect4.5%2.5%$51.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$51.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$31.5M+122bp9mo
Clean Claim Rate88.0%96.0%$1.7M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$54.3M
Cost to Collect
$51.7M
Denial Rate Reduction
$51.2M
A/R Days Reduction
$31.5M
Clean Claim Rate
$1.7M
Total EBITDA Uplift$190.3M
Current EBITDA$-993.3M
+ RCM Uplift+$190.3M
Pro Forma EBITDA$-803.1M
Current Margin-38.4%
Pro Forma Margin-31.1%
WC Released (1x)$99.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.53B$-4.65B0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.53B$-5.61B0.00x-100.0%
Bull Case9.0x11.0x$-1.38B$-5.48B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.38B$-6.38B0.00x-100.0%
Bear Case11.0x10.0x$-1.68B$-5.10B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.68B$-6.16B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 292 hospitals with 478-1910 beds
  • Same-state prioritization (n=3)
  • Comp margins: P25=-14.8% / P50=-4.3% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.